Your shopping cart is currently empty

KSI-3716 is a c-Myc inhibitor used as a bladder chemotherapy agent. It blocks the formation of the c-MYC/MAX complex with the target gene promoter and induces cell cycle arrest and apoptosis. It can be used for bladder cancer research.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $149 | 5 days | 5 days | |
| 5 mg | Preferential | 5 days | 5 days |
| Description | KSI-3716 is a c-Myc inhibitor used as a bladder chemotherapy agent. It blocks the formation of the c-MYC/MAX complex with the target gene promoter and induces cell cycle arrest and apoptosis. It can be used for bladder cancer research. |
| Targets&IC50 | c-Myc:0.86 μM |
| In vitro | KSI-3716 is a potent c-Myc inhibitor that blocks the binding of c-MYC/MAX to target gene promoters. KSI-3716 is used as an intravesical chemotherapy agent. KSI-3716 effectively blocks complex formation in a dose-dependent manner, IC50 0.86 μM. C-myc-mediated transcription activity was inhibited by KSI-3716 at concentrations as low as 1 μM. KSI-3716 has cytotoxic effects on bladder cancer cells by inducing cell cycle arrest and apoptosis. [1] |
| In vivo | KSI-3716 was injected into the bladder of mice xenografted with bladder cancer at a dose of 5 mg/kg, and it was observed that it could significantly inhibit tumor growth and had little systemic toxicity. [1] |
| Synonyms | KSI3716 |
| Molecular Weight | 426.09 |
| Formula | C17H11BrCl2N2O2 |
| Cas No. | 1151813-61-4 |
| Smiles | O=C1C=2C(Cl)=CC=C(Br)C2NC(NC3=CC=C(Cl)C=C3)=C1C(=O)C |
| Relative Density. | 1.675 g/cm3 (Predicted) |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||
| Solubility Information | DMSO: 2 mg/mL (4.69 mM), Sonication is recommended. | ||||||||||
Solution Preparation Table | |||||||||||
DMSO
| |||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.